Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas

Survival following anthracycline-based chemotherapy remains poor among patients with most T-cell lymphoproliferative disorders. This may be attributed, at least in part, to cell-autonomous mechanisms of chemotherapy resistance observed in these lymphomas, including the loss of important tumor suppre...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Murga-Zamalloa, Carlos, Polk, Avery, Hanel, Walter, Chowdhury, Pinki, Brown, Noah, Hristov, Alexandra C., Bailey, Nathanael G., Wang, Tianjiao, Phillips, Tycel, Devata, Sumana, Poonnen, Pradeep, Gomez-Gelvez, Juan, Inamdar, Kedar V., Wilcox, Ryan A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777707/
https://ncbi.nlm.nih.gov/pubmed/29383095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22967
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi